In this MEDtalk Peter Schmid present updated data for overall survival from Impassion 130-study – a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer. This 2nd IMpassion130 interim OS analysis confirming clinically meaningful OS benefit of this treatment ...

Progression-free and overall survival were significantly improved with first line treatment with pertuzumab, trastuzumab, and docetaxel in 808 pts with HER2-positive metastatic breast cancer. OS was increased by an unprecedented 15.7 month. In this MEDtalk Sandra M. Swain present the end-of-study analysis with a median follow-up of 99 month (max 120 mo). a ...

The 2010 Affordable Care Act, ACA, expanded access to insurance and care for many Americans. In this MEdtalks Anna Jo Smith evaluate the impact of the ACA on stage at diagnosis and time to treatment for women with ovarian ...

In this MEDtalk Kamal Chamoun explain, why nsurance type and regional income are associated with Multiple Myeloma survival. This may be related to affordability of oral antineoplastic medications. Prices have been rapidly escalating and there are well described issues with ...

The Phase III MONALEESA-7 study demonstrated that the addition of ribociclib to a nonsteroidal aromatase inhibitor or tamoxifen + goserelin significantly extended progression-free survival. In this MEDtalk Yen-Shen Lu explain the effect across gene expression ...

Locally advanced or metastatic urothelial cancer remains a lethal disease with limited treatment options for patients who progress on or after platinum and/or checkpoint inhibitor (CPI). In this MEDtalk Daniel Peter Petrylak present a new streatment of urothelial cancer Enfortumab vedotin (EV) – an antibody-drugconjugate targeting Nectin-4, which is highly expressed in UC. This study demonstrate the fact, that Enfortumab vedotin have a therapy that can help people who don’t benefit from checkpoint ...

In this MEDtalk Michael R. Migden report from a 12-month follow-up study from a primary analysis of cemiplimab, a human monoclonal anti-pd-1, in patients with metastatic cutaneous squamous cell carcinoma.  Objective response rate was 49.2% and median progression-free survival was 18.4 months. According to Michael R. Migden are cemiplimab a paradigm shift in treatment of these group of ...

In this MEDtalk Daniel Heinrich present which new data about prostate and kidney cancer he finds most ...

Lurbinectedin is a novel anticancer drug that inhibits activated transcription and induces DNA double-strand breaks, leading to apoptosis. In this MEDtalk Bjørn Henning Grønberg explain, why he think, that Lurbinectedin is a new promising drug for second-line SCLC ...

Standard first-line therapy for EGFR mutant advanced non-small cell lung cancer (NSCLC) is an EGFR-directed oral TKI. Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged progression free and overall survival but also increased toxicity. The data from this study support, that pemetrexed-carboplatin-gefitinib represents a new standard first-line therapy for EGFR mutant ...

#Senaste tidskrift

Diabetes / hjärt-kärlsjukdomar

Nr. 33 • juni 2019
Årgång 9
  • Typ 2-diabetes
  • PCSK9-hämmare
  • Förmaksflimmer